Published on 09/12/2025

Carryover and Memory Effects: Cleaning and Cross-Contamination Control

The recent advancements in pharmaceutical manufacturing and packaging underscore the importance of robust cleaning practices to mitigate carryover and memory effects, particularly regarding extractables and leachables (E&L). This guide aims to provide a comprehensive overview and step-by-step tutorial for pharmaceutical professionals involved in maintaining compliance with regulations such as the FDA’s process validation requirements and the EU GMP Annex 1.

Understanding Extractables and Leachables (E&L)

Extractables and leachables refer to the chemical substances that can migrate from the packaging or components into the drug product. Understanding these terms is crucial in ensuring drug safety and efficacy.

Extractables are substances that can be released from the packaging material under extreme extraction conditions. They are identified during the testing phase and represent the maximum potential exposure. In contrast, leachables are the substances that actually migrate into the drug product under normal storage and usage conditions. The importance of evaluating both lies in their potential impact on product integrity and patient safety.

The evaluation of E&L is a regulatory requirement as per USP and FDA guidelines. It is crucial to conduct a thorough E&L risk assessment to identify which materials pose a risk of extractables and leachables, based on factors such as the material composition and drug formulation.

Regulatory Framework for E&L Testing

Pharmaceutical companies must follow stringent guidelines and regulations regarding E&L to ensure compliance and patient safety. Regulations set forth by authorities such as the FDA, EMA, and PIC/S provide a framework for conducting E&L studies.

According to the FDA, manufacturers should consider the analytical evaluation threshold (AET) and dose-based threshold (DBT) when performing E&L assessments. The AET is defined as the lowest concentration of a leachable that could be detected and poses no risk to the patient. The DBT, on the other hand, is aligned with the patient’s exposure to the drug product.

Reference to the FDA provides essential guidance on conducting E&L studies. Following the framework set by these agencies ensures a well-designed risk assessment that complies with regulatory expectations.

Step 1: E&L Risk Assessment

A comprehensive E&L risk assessment is essential for identifying potential contaminants and their risks associated with pharmaceutical products.

• Material Assessment: Evaluate the materials in contact with the drug product, including elastomers, polymers, and other packaging materials.
• Historical Data Review: Examine previous E&L studies, including any adverse events related to leachables.
• Identify Potential Sources: Catalog all components that may contribute to E&L and assess their compatibility with the drug formulation.

By methodically assessing the materials and their historical performance, pharmaceutical manufacturers can identify potential risks and appropriately plan E&L testing protocols.

Step 2: Designing E&L Studies

The design of E&L studies is critical. It should align with regulatory expectations while providing defensible data.

Study Design Considerations:

• Extraction Conditions: Define the extraction conditions to simulate worst-case scenarios, including temperature, solvents, and time exposure.
• Sample Size: Determine the appropriate sample sizes based on the statistical analysis plans to ensure representativeness.
• Analytical Techniques: Select fit-for-purpose analytical methods such as LC-MS, GC-MS, or others to assess both extractables and leachables.

The study design must ensure that it comprehensively evaluates both extractables and leachables, conforming to the guidelines specified by regulatory entities. Following quality standards, such as those outlined in the PQRI guideline, ensures the study is robust and defensible during inspections.

Step 3: Conducting the Experiments

Once the study design is finalized, the next step involves executing the experiments following Good Laboratory Practices (GLP). Ensure that proper documentation exists throughout the study process to facilitate tracking and compliance.

• Implementation of Protocols: Adhere strictly to the experimental protocols decided in the study design to avoid any deviations that could affect the validity of the results.
• Monitoring Conditions: Ensure that the experimental conditions are monitored to be consistent with the defined extraction parameters.
• Documentation: Maintain thorough documentation of all procedures, conditions, and results to provide a clear trail for regulatory inspection and audit purposes.

After conducting the experiments, compile the data for analysis while ensuring traceability of all materials and methods used throughout the study.

Step 4: Data Analysis and Reporting

The analysis phase is crucial for interpreting the results collected from the E&L study.

• Quantification: Quantify the extractables and leachables detected during the testing process using the selected analytical methods.
• Risk Evaluation: Evaluate the obtained results against the established AET and DBT to assess their safety margin.
• Report Generation: Prepare a comprehensive report detailing the methodology, results, and conclusions reached based on the data analysis.

This report serves as a formal record of the findings and may be submitted to regulatory agencies for regulatory approval of the product packaging and components used in the drug product.

Step 5: Container Closure Integrity (CCI) Testing

Prominent among the considerations of E&L is ensuring container closure integrity (CCI). CCI is a critical quality attribute affecting the stability and safety of pharmaceutical products.

Interdependencies exist between E&L results and CCI assessments. Hence, manufacturers must integrate CCI assessments into their E&L studies. This testing should include evaluations under typical and extreme conditions to assess how the closure system interacts with the drug product over time.

Regulatory guidance from bodies such as the EMA emphasizes the need for robust CCI testing as part of the overall risk management system for drug products. This protective measure aids in ensuring the patient’s safety and the product’s efficacy throughout its shelf life.

Step 6: Single-Use Systems Validation

Single-use systems are becoming an essential component of modern pharmaceutical manufacturing. Validating these systems becomes crucial to prevent cross-contamination and ensure compliance with regulations.

• Validation Protocols: Develop and implement validation protocols specific to single-use systems that include cleaning procedures, performance qualifications, and compatibility assessments.
• Ongoing Monitoring: Implement a program for ongoing monitoring and audits of single-use systems to ensure compliance over time.

The validation process should also recognize the need for integration with E&L assessments to evaluate the risk of extractables and leachables from these systems as well. Documentation of results and any changes in processes should contribute to a continuous improvement framework.

Conclusion

Effective management of carryover and memory effects through rigorous cleaning and cross-contamination controls is paramount for ensuring pharmaceutical product safety. The steps outlined in this guide serve as a framework for conducting compliant, scientifically sound E&L assessments in line with regulatory expectations.

By implementing a thorough approach to E&L risk assessments, study designs, data analysis, and CCI testing, pharmaceutical companies can position themselves to meet industry standards and safeguard public health. Remember to consistently reference regulatory guidelines from the FDA, EMA, MHRA, and others to remain informed about best practices in extractables and leachables evaluation.